Decrease in serum prolactin levels after long-acting injectable aripiprazole treatment: a case report

Abstract

Hyperprolactinemia is a severe problem which involves galactorrhea, amenorrhea, sexual dysfunction, and loweredbone mineral density. It can be a long-lasting problem belongs to the atypical antipsychotics that impairs treatmentadherence and quality of life in patients with schizophrenia. The paliperidone palmitate may cause hyperprolactinemiaand there are different approaches in management of this adverse event. Adding oral aripiprazole was shown to beuseful in the treatment of hyperprolactinemia due to paliperidone palmitate. Now the new drug long-acting Injectable(LAI) aripiprazole may become a possible new agent in treatment of schizophrenia patients with paliperidone palmitateinduced hyperprolactinemia.